In nearly 60 warning letters, the FDA took telehealth companies and other providers to task for false and misleading claims ...

Research indicates that external eating behavior is a key predictor of weight loss in type 2 diabetes patients receiving ...

In a phase 3 trial, once-daily oral orforglipron induced significant, dose-dependent weight loss over 72 weeks in adults with ...

GLP-1 patches for weight loss have made the scene—but a leading MD warns you they aren't the same as the more familiar ...

The two observational studies have limitations, including use of older GLP-1s, but still point to the strengths of bariatric ...

Eli Lilly and Company (NYSE: LLY) has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks ...

Hims & Hers Health stock is a compelling buy amid growth, undervaluation, and expanding markets. Click here to read the ...

Cookbook author and model Chrissy Teigen shared that she was in a “deep depression” after the 2020 loss of her son Jack.

Rebel Wilson announced a partnership with the subscription-based wellness platform Noom on Thursday as its chief wellness ambassador ...

Researchers have found bariatric surgery to be more cost-effective for treating patients with obesity compared with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to new study ...

This multicenter, prospective observational study is published in Frontiers in Clinical Diabetes and Healthcare. “Pre-treatment assessment of eating behavior patterns may help predict who will benefit ...

The popularity of glucagon-like peptide-1 (GLP-1) agonists like Ozempic, Wegovy and Mounjaro has exploded in recent years.